You are here: Industry Insights > Market News > Novartis aims to bottle more than 50 mln doses of BioNTech COVID-19 vaccine in 2021

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Novartis aims to bottle more than 50 mln doses of BioNTech COVID-19 vaccine in 2021

firstwordpharmaJune 23, 2021

Tag: Novartis , BioNTech , COVID-19 , Vaccine

Favorites

Novartis aims to bottle more than 50 million doses of BioNTech’s COVID-19 vaccine this year at its fill-and-finish facility in Stein, Switzerland, as reported in KFGO.

Novartis aims to bottle more than 50 mln doses of BioNTech COVID-19 vaccine in 2021

The news comes after the European Union’s drug regulator approved the bottling plant.

Previous:Cyteir Therapeutics Announces Closing of Initial Public Offering

Next:Century Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

PharmaSourcesMay 21, 2024

The first patient has been dosed in a clinical trial of the Company's BCL2 inhibitor, ICP-248, in combination with orelabrutinib as a first-line therapy for chronic lymphocytic leukemia /small lymphocytic lymphoma (CLL/SLL) in China.

Selection of Commercial Models for Innovative Drugs

PharmaSourcesMay 21, 2024

Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA

Biotech NewswireMay 17, 2024

Novartis aims to bottle more than 50 mln doses of BioNTech COVID-19 vaccine in 2021 | Pharmasources.com

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

PharmaSourcesMay 16, 2024

InnoCare announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, for the treatment of psoriasis.

Novartis aims to bottle more than 50 mln doses of BioNTech COVID-19 vaccine in 2021

Related News

InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

Selection of Commercial Models for Innovative Drugs

Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

You may like